ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 25.44

+2.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	6/5/2005 11:41:11 AM
	Read Replies (1) of 588

USE OF THE LIPOXIN RECEPTOR, FPRL1, AS A TOOL FOR IDENTIFYING COMPOUNDS EFFECTIVE IN THE TREATMENT OF PAIN AND INFLAMMATION Patent number: WO2005047899 Publication date: 2005-05-26 Inventor: NASH NORMAN (US); SCULLY AUDRA L (US); GARDELL LUIS (US); OLSSON ROGER (SE); GUSTAFSSON MAGNUS (DK) Applicant: ACADIA PHARM INC (US);; NASH NORMAN (US);; SCULLY AUDRA L (US);; GARDELL LUIS (US);; OLSSON ROGER (SE);; GUSTAFSSON MAGNUS (DK) Application number: WO2004US36952 20041104 Priority number(s): US20030518476P 20031107; US20030519085P 20031110; US20040592926P 20040730 Abstract of WO2005047899 Disclosed herein are compounds that selectively activate the FPRL1 receptor. Further disclosed are methods of alleviating inflammatory responses by regulating key steps in leukocyte trafficking and preventing neutrophil-mediated tissue damage by administering to a subject a therapeutically effective amount of the compounds disclosed herein. In addition, methods of modulating, or specifically agonizing, the FPRL1 receptor by administering an effective amount of the compounds disclosed herein are provided.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next